NIKKEI 225
32,678.62 +276.21 (+0.85%) HANG SENG
17,729.29 -328.16 (-1.82%) CRUDE OIL
89.88 -0.15 (-0.17%) GOLD FUTURES
1,934.80 -10.80 (-0.56%) DOW
33,954.15 -9.69 (-0.03%) Bitcoin GBP
21,538.42 -146.87 (-0.68%)
BioSenic S.A. (0R55.L)
| Previous close | 0.0920 |
| Open | 0.0900 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0850 - 0.1295 |
| 52-week range | 0.0250 - 0.3455 |
| Volume | |
| Avg. volume | 40,871 |
| Market cap | 10,425 |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7670 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireBioSenic publishes new evidence of beneficial effects of arsenic trioxide treatment supporting clinical trial for systemic sclerosis
INSIDE INFORMATIONS BioSenic publishes new evidence of beneficial effects of arsenic trioxide treatment supporting clinical trial for systemic sclerosis Arsenic trioxide (ATO) therapeutic potential to treat systemic sclerosis (SSc) is now confirmed in a new preclinical model - Fra2- characterized by severe pulmonary lesions Mont-Saint-Guibert, Belgium, September 19, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune an
- Globe Newswire
BioSenic reaches agreement on binding term sheets with main creditors to restructure past financial debts
INSIDE INFORMATION New binding term sheets have been formulated upon for the replacement of the Monument and Patronale bonds and loans by new unsecured convertible bonds as well as for the long-term extension of the past loan financing with the European Investment Bank. Mont-Saint-Guibert, Belgium, September 14, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announc
- Globe Newswire
BioSenic reports half year 2023 results
REGULATED INFORMATION The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Biosenic in the section ‘Financial reports’. BioSenic publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the repor
